MENU

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  223.83
+1.27 (0.57%)
AAPL  274.99
+0.38 (0.14%)
AMD  201.46
-7.71 (-3.69%)
BAC  54.98
+0.16 (0.30%)
GOOG  300.44
-7.29 (-2.37%)
META  657.00
-0.15 (-0.02%)
MSFT  476.77
+0.38 (0.08%)
NVDA  171.70
-6.02 (-3.39%)
ORCL  178.24
-10.41 (-5.52%)
TSLA  477.94
-11.94 (-2.44%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
TOP
Email a Story